Truist Securities Raises Rating on STRO $STRO
Key Points
- Truist Securities now rates Sutro Biopharma, Inc. ($STRO) "buy" with a $50 target.
- Truist Securities's $50 price target implies 89.75% upside from Sutro Biopharma, Inc.'s ($STRO) current $26.35 share price.
- The Street's average $STRO price target is $47.23 (Strong Buy).
- $STRO last traded around $26.35.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Truist Securities raised its rating on Sutro Biopharma, Inc. ($STRO) to a "buy" rating in a recent research note and set a price target of $50, a 89.75% upside from the current price.
Sutro Biopharma, Inc. Stock Up 28.9%
Shares of Sutro Biopharma, Inc. ($STRO) traded around $26.35 on Saturday, up 28.9% for the day.
Sutro Biopharma, Inc. Earnings
Analysts Set New Price Targets
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Get Sutro Biopharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $STRO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.